Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 3/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 3/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502627 | 0.94 | MAP3K8 (0.35) | MAP3K8KRASRXRARXRBRXRG | |
| SCHEMBL6508509 | 0.94 | PTGDR2 (0.35) | MAP3K8KRAS | |
| SCHEMBL6510542 | 0.93 | MAP3K8 (0.36) | MAP3K8KRASRXRARXRBRXRG | |
| SCHEMBL6503910 | 0.93 | MAP3K8 (0.33) | MAP3K8KRASRXRARXRBRXRG | |
| SCHEMBL6506250 | 0.93 | KRAS (0.34) | MAP3K8KRAS | |
| SCHEMBL6502580 | 0.93 | KRAS (0.33) | MAP3K8KRASRXRARXRBRXRG | |
| SCHEMBL6507271 | 0.93 | MAP3K8 (0.34) | MAP3K8KRASATRBTK | |
| SCHEMBL6506433 | 0.93 | FGFR1 (0.35) | MAP3K8KRASATR | |
| SCHEMBL6510555 | 0.93 | MAP3K8 (0.35) | MAP3K8KRASRXRARXRBRXRG | |
| SCHEMBL6503244 | 0.93 | MAP3K8 (0.34) | MAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | MAP3K8 143/4885NPY5R 1889/4885KRAS 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.